The pharmaceutical and nutraceutical ingredients landscape is shifting as Lone Star Funds has reached a definitive agreement to acquire Lonza Group AG’s Capsules &. Health Ingredients (CHI) division for an enterprise value of CHF 2.3 billion (approximately USD 3 billion, as of March 6, 2026). This strategic move, announced today, will see Lonza retain a significant 40% equity position in the business, signaling a continued, albeit altered, partnership. The deal is expected to finalize in the second half of 2026, subject to standard regulatory approvals and closing conditions.
This acquisition represents a significant development for both companies. For Lonza, a global leader in pharmaceutical, biotech and specialty ingredient manufacturing, it marks a key step in its transformation to a focused Contract Development and Manufacturing Organization (CDMO). The divestiture allows Lonza to concentrate its resources and expertise on its core CDMO offerings, streamlining its operations and bolstering its position in a rapidly evolving market. For Lone Star Funds, a private equity firm specializing in global investments, the acquisition of CHI presents an opportunity to capitalize on a well-established, globally recognized platform with strong technical capabilities and a diverse product portfolio.
Lone Star Funds Acquires Capsules & Health Ingredients: A Deep Dive
Headquartered in Basel, Switzerland, Capsules & Health Ingredients operates across the Americas, Europe, and the Asia-Pacific region. The CHI division is structured around three core segments: Hard Empty Capsules, Dosage Form Solutions, and Health Ingredients. The Hard Empty Capsules segment is a leading global manufacturer of both gelatin and plant-based capsules, catering to the pharmaceutical and nutraceutical industries with innovative solutions. Dosage Form Solutions provides end-to-end development and manufacturing services for nutraceutical and pharmaceutical clients, whereas Health Ingredients focuses on branded, science-backed nutritional ingredients targeting joint health, energy, and active lifestyle markets. This diversified portfolio positions CHI as a key player in several high-growth sectors.
According to the official announcement, Lone Star believes CHI possesses a “high-quality, globally recognized platform” with established customer relationships. The firm intends to operate CHI as an independent entity, focusing on enhancing operational efficiency, investing in research and development, and pursuing strategic growth initiatives within its core segments. This independent structure is expected to provide CHI with greater flexibility and agility to respond to market demands and capitalize on emerging opportunities. The attractiveness of the markets CHI serves, characterized by strong underlying demand growth, further reinforces Lone Star’s confidence in the acquisition.
Lonza’s Strategic Shift and Financial Details
The decision to divest CHI is a direct result of Lonza’s ongoing strategic transformation. The company has been actively reshaping its portfolio to concentrate on its core CDMO business, which offers higher growth potential, and margins. Lonza’s official statement confirms that the transaction will generate upfront proceeds of CHF 1.7 billion (approximately USD 2.2 billion) and the retained 40% stake in CHI provides potential for future value creation. Lonza will benefit from a preferential participation in any future exit of the business, offering additional financial upside.
This move aligns with the broader industry trend of specialization and focus. CDMOs like Lonza are increasingly sought after by pharmaceutical and biotech companies looking to outsource drug development and manufacturing processes. By streamlining its operations and concentrating on its CDMO capabilities, Lonza aims to strengthen its competitive position and capitalize on the growing demand for outsourced manufacturing services. The company’s commitment to innovation and its strong track record in complex manufacturing processes are key differentiators in this competitive landscape.
Lone Star’s Investment Strategy and CHI’s Future Outlook
Lone Star Funds, founded in 1995, has a long history of investing in companies across various sectors, including healthcare, real estate, and financial services. The firm manages approximately USD 95 billion in assets across 25 private equity funds, according to information on their official website. Their investment strategy typically involves acquiring underperforming or undervalued businesses and implementing operational improvements to enhance their value.
Donald Quintin, Chief Executive Officer of Lone Star, expressed optimism about CHI’s potential as a standalone business. “The company has leading positions, a global footprint and a strong heritage of product quality and innovation,” Quintin stated. “We believe that, as an independent operator, CHI will benefit from greater strategic flexibility and targeted investments to accelerate its growth, improve its operational performance and continue to deliver value to customers around the world.” This suggests Lone Star intends to invest in CHI’s existing strengths and explore latest opportunities for expansion and innovation.
Impact on the Pharmaceutical and Nutraceutical Industries
The acquisition of CHI by Lone Star Funds is likely to have ripple effects throughout the pharmaceutical and nutraceutical industries. The increased focus on operational efficiency and innovation under Lone Star’s ownership could lead to improved product quality, faster development cycles, and more competitive pricing. The continued partnership with Lonza, through the retained 40% equity stake, could likewise foster collaboration and knowledge sharing between the two companies.
the transaction highlights the growing demand for high-quality ingredients and manufacturing services in the health and wellness sector. Consumers are increasingly focused on preventative healthcare and are seeking out products that support their overall well-being. This trend is driving growth in the nutraceutical market, creating opportunities for companies like CHI to expand their product offerings and reach new customers. The Health Ingredients segment, in particular, is well-positioned to benefit from this growing demand.
Key Takeaways
- Lone Star Funds is acquiring Lonza’s Capsules & Health Ingredients (CHI) division for CHF 2.3 billion.
- Lonza will retain a 40% equity stake in CHI and benefit from future exit participation.
- The acquisition aligns with Lonza’s strategic shift towards becoming a pure-play CDMO.
- Lone Star plans to operate CHI as an independent entity, focusing on operational improvements and growth initiatives.
- The transaction is expected to close in the second half of 2026, subject to regulatory approvals.
The completion of this deal will be closely watched by industry analysts and stakeholders. The success of Lone Star’s investment will depend on its ability to effectively integrate CHI into its portfolio and execute its strategic plan. The continued collaboration between Lone Star and Lonza will also be a key factor in shaping the future of the business. As the pharmaceutical and nutraceutical industries continue to evolve, CHI is poised to play a significant role in meeting the growing demand for innovative and high-quality ingredients and manufacturing solutions.
The next step in this process will be the fulfillment of the necessary regulatory approvals and conditions for the transaction to close, anticipated in the latter half of 2026. We will continue to monitor this development and provide updates as they become available. Share your thoughts on this acquisition and its potential impact on the industry in the comments below.